US Health Officials Ditch Black Box Warnings for Hormone Therapy Treatments, Hoping to Boost Use
In a major shift, US health officials announced Monday that they will be removing warnings about the increased risk of breast cancer, heart disease, and dementia associated with hormone replacement therapy (HRT) products used to treat menopause and perimenopause symptoms.
The decision comes after decades of controversy surrounding HRT, which was initially linked to an increased risk of these conditions in a 2002 study known as the Women's Health Initiative. However, subsequent research has questioned the validity of this study, and medical associations have called for revisions to the labels.
According to FDA Commissioner Marty Makary, "We now have a more nuanced understanding" of HRT's risks and benefits, and want to put the fear surrounding it into perspective. He argued that hormone therapy is an effective treatment option for menopause symptoms, one that can improve women's health on a population level.
The updated labels will recommend HRT for patients under 60 or within 10 years of menopause onset, while estrogen-only products will still carry warnings about endometrial cancer. However, the FDA has also approved a new generic version of Premarin and a non-hormonal treatment for hot flashes.
Critics argue that the removal of these warnings is an "incredible step forward" to empower millions of women to live longer, healthier lives. With HRT replacing estrogen production in postmenopausal women, which typically ceases at age 52, systemic therapy and low-dose vaginal estrogen are two main treatment options.
The FDA's decision comes as a surprise, but experts say it is a much-needed shift towards balancing the risks and benefits of HRT. "Estrogen is a key hormone for women's health," notes Alicia Jackson, director of the Advanced Research Projects Agency for Health.
In a major shift, US health officials announced Monday that they will be removing warnings about the increased risk of breast cancer, heart disease, and dementia associated with hormone replacement therapy (HRT) products used to treat menopause and perimenopause symptoms.
The decision comes after decades of controversy surrounding HRT, which was initially linked to an increased risk of these conditions in a 2002 study known as the Women's Health Initiative. However, subsequent research has questioned the validity of this study, and medical associations have called for revisions to the labels.
According to FDA Commissioner Marty Makary, "We now have a more nuanced understanding" of HRT's risks and benefits, and want to put the fear surrounding it into perspective. He argued that hormone therapy is an effective treatment option for menopause symptoms, one that can improve women's health on a population level.
The updated labels will recommend HRT for patients under 60 or within 10 years of menopause onset, while estrogen-only products will still carry warnings about endometrial cancer. However, the FDA has also approved a new generic version of Premarin and a non-hormonal treatment for hot flashes.
Critics argue that the removal of these warnings is an "incredible step forward" to empower millions of women to live longer, healthier lives. With HRT replacing estrogen production in postmenopausal women, which typically ceases at age 52, systemic therapy and low-dose vaginal estrogen are two main treatment options.
The FDA's decision comes as a surprise, but experts say it is a much-needed shift towards balancing the risks and benefits of HRT. "Estrogen is a key hormone for women's health," notes Alicia Jackson, director of the Advanced Research Projects Agency for Health.